Imiquimod 5% cream induced psoriasis: A case report, summary of the literature and mechanism

British Journal of Dermatology

Volumn 164, Issue 3, 2011, Pages 670-672

  Patel, U ^a   Mark, N M ^a   MacHler, B C ^a   Levine, V J ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CLOBETASOL; IMIQUIMOD; INTERLEUKIN 17; INTERLEUKIN 17 RECEPTOR; INTERLEUKIN 23; INTERLEUKIN 23 RECEPTOR; TOLL LIKE RECEPTOR 7;

ACTINIC KERATOSIS; AGED; BASAL CELL CARCINOMA; CASE REPORT; CELL ACTIVATION; CYTOKINE PRODUCTION; DENDRITIC CELL; ERYTHEMA; HUMAN; LETTER; MALE; MEDICAL HISTORY; NAIL DYSTROPHY; PHOTOTHERAPY; PRIORITY JOURNAL; PSORIASIS; SEBORRHEIC DERMATITIS; SKIN BIOPSY; SKIN PRURITUS; TH1 CELL; TH17 CELL; ULTRAVIOLET B RADIATION;

ADJUVANTS, IMMUNOLOGIC; AGED; AMINOQUINOLINES; ANTI-INFLAMMATORY AGENTS; BIOPSY; CLOBETASOL; HUMANS; KERATOSIS, ACTINIC; MALE; PSORIASIS; TREATMENT OUTCOME; ULTRAVIOLET THERAPY;

EID: 79952383537     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2010.10124.x     Document Type: Letter

References (21)

1. Fanti PA, Dika E, Vaccari S, et al. Generalized psoriasis induced by topical treatment of actinic keratosis with imiquimod. Int J Dermatol 2006; 45: 1464-5. (Pubitemid 44869771)
2. Gilliet M, Conrad C, Geiges M, et al. Psoriasis triggered by toll-like receptor 7 agonist imiquimod in the presence of dermal plasmacytoid dendritic cell precursors. Arch Dermatol 2004; 140: 1490-5. (Pubitemid 39627441)
3. Rajan N, Langtry JA,. Generalized exacerbation of psoriasis associated with imiquimod cream treatment of superficial basal cell carcinomas. Clin Exp Dermatol 2006; 31: 140-1.
4. Wu JK, Siller G, Strutton G,. Psoriasis induced by topical imiquimod. Australas J Dermatol 2004; 45: 47-50. (Pubitemid 38315850)
5. Garcia-Lora E, Tercedor J, Massare E, et al. Interferon-induced psoriasis in a patient with chronic hepatitis C. Dermatology 1993; 187: 280. (Pubitemid 23333941)
6. Ladoyanni E, Nambi R,. Psoriasis exacerbated by interferon-alpha in a patient with chronic myeloid leukemia. J Drugs Dermatol 2005; 4: 221-2.
7. Kowalzick L,. Psoriasis flare caused by recombinant interferon beta injections. J Am Acad Dermatol 1997; 36: 501. (Pubitemid 27131991)
8. van der Fits L, van der Wel LI, Laman JD, et al. In psoriasis lesional skin the type I interferon signaling pathway is activated, whereas interferon-alpha sensitivity is unaltered. J Invest Dermatol 2004; 122: 51-60. (Pubitemid 38114638)
9. Eriksen KW, Lovato P, Skov L, et al. Increased sensitivity to interferon-alpha in psoriatic T cells. J Invest Dermatol 2005; 125: 936-44.
10. Hida S, Ogasawara K, Sato K, et al. CD8(+) T cell-mediated skin disease in mice lacking IRF-2, the transcriptional attenuator of interferon-alpha/beta signaling. Immunity 2000; 13: 643-55.
11. Nestle FO, Conrad C, Tun-Kyi A, et al. Plasmacytoid predendritic cells initiate psoriasis through interferon-alpha production. J Exp Med 2005; 202: 135-43. (Pubitemid 41002916)
12. Bissonnette R, Papp K, Maari C, et al. A randomized, double-blind, placebo-controlled, phase I study of MEDI-545, an anti-interferon-alfa monoclonal antibody, in subjects with chronic psoriasis. J Am Acad Dermatol 2010; 62: 427-36.
13. Miller RL, Gerster JF, Owens ML, et al. Imiquimod applied topically: a novel immune response modifier and new class of drug. Int J Immunopharmacol 1999; 21: 1-14. (Pubitemid 29097684)
14. Palamara F, Meindl S, Holcmann M, et al. Identification and characterization of pDC-like cells in normal mouse skin and melanomas treated with imiquimod. J Immunol 2004; 173: 3051-61. (Pubitemid 39142011)
15. Mohty M, Vialle-Castellano A, Nunes JA, et al. IFN-alpha skews monocyte differentiation into Toll-like receptor 7-expressing dendritic cells with potent functional activities. J Immunol 2003; 171: 3385-93. (Pubitemid 37254538)
16. Schon MP, Schon M,. Imiquimod: mode of action. Br J Dermatol 2007; 157 (Suppl. 2): 8-13. (Pubitemid 350179622)
17. Kono T, Kondo S, Pastore S, et al. Effects of a novel topical immunomodulator, imiquimod, on keratinocyte cytokine gene expression. Lymphokine Cytokine Res 1994; 13: 71-6. (Pubitemid 24136345)
18. Lebre MC, van der Aar AM, van Baarsen L, et al. Human keratinocytes express functional Toll-like receptor 3, 4, 5, and 9. J Invest Dermatol 2007; 127: 331-41. (Pubitemid 46106911)
19. Schon MP, Schon M, Klotz KN,. The small antitumoral immune response modifier imiquimod interacts with adenosine receptor signaling in a TLR7- and TLR8-independent fashion. J Invest Dermatol 2006; 126: 1338-47. (Pubitemid 43997917)
20. Zagon IS, Donahue RN, Rogosnitzky M, McLaughlin PJ,. Imiquimod upregulates the opioid growth factor receptor to inhibit cell proliferation independent of immune function. Exp Biol Med (Maywood) 2008; 233: 968-79.
21. van der Fits L, Mourits S, Voerman JS, et al. Imiquimod-induced psoriasis-like skin inflammation in mice is mediated via the IL-23/IL-17 axis. J Immunol 2009; 182: 5836-45.